VEGFA and glycogen storage disease VI: Hence, the inhibition of tumor angiogenesis by interfering with the VEGF pathway either by the direct inhibition of VEGF (e.g., Bevacizumab) or by the inhibition of autophosphorylation of VEGFR2 (e.g., sunitinib, sorafenib) has become a therapeutic target for cancer therapy and other angiogenesis-dependent diseases [25,26,27].